A Revolution in NAMD Treatment: PharmAbcine Doses its First Patient with a Promising TIE2 Agonistic Antibody

PharmAbcine Inc. (KOSDAQ: 208340ks) is thrilled to announce the first patient in the Phase I clinical trial of PMC-403, its groundbreaking TIE2 agonistic antibody, has been successfully dosed.

The innovative antibody has the potential to treat neovascular age-related macular degeneration (nAMD), a medical condition one in six adults over the age of 55 suffer as their eyesight struggles to keep up with age. This groundbreaking trial is a critical step forward in expanding out the current treatment options for nAMD sufferers, and PharmAbcine is proud to be the leader in this field.

The exciting new Phase I clinical trial has kicked off with the first of 36 planned participants dosed. Taking place in multi-center hospitals across South Korea, including Seoul National University Bundang Hospital, this single and multiple ascending-dose open-label study is poised to set the stage for further exploration of a promising new pharmaceutical option.

The present study seeks to determine the safety, efficacy, and pharmacokinetics of PMC-403, a potential treatment for neovascular and non-neovascular age-related macular degeneration (nAMD).

With this knowledge, we hope to identify the maximum tolerated dose (MTD) and recommend a Phase 2 dose (RP2D), along with any potential benefits to those suffering from this sight-threatening condition.

PharmAbcine’s PMC-403 is a revolutionary first-in-class antibody that has the potential to treat Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR), and possibly even more systematic vessel-related diseases.

It aims to normalize and stabilize pathologically leaky blood vessels by binding to the TIE2 receptor, which is exclusively expressed on the surface of vascular endothelial cells. Unlike anything before it, PMC-403 is being developed to revolutionize how we approach and treat vessel-related diseases.

Dr. Sagong Min, Professor of Yeungnam University Hospital, made headlines when he conducted the world’s first ophthalmology trial using Tie2 activation antibodies. He explained that the antibody, ‘PMC-403’, developed by PharmAbcine, could stabilize abnormal blood vessels and reduce leakage, providing a much-needed treatment option for patients who don’t respond or have beome relapsed to existing anti-VEGF drugs. It was an exciting development in the field and will surely benefit many patients in the future.

PharmAbcine’s Dr. Jin-San Yoo, CEO, is thrilled that the clinical trial for PMC-403 is underway. This therapy is a potential breakthrough for those suffering from nAMD, a prevalent vessel-related ocular disease without any alternative therapeutic options for those who have not responded or have relapsed to existing anti-VEGF drugs. If positive results are demonstrated, PMC-403 will revolutionize the ophthalmology field!

About PharmAbcine Inc.

PharmAbcine is transforming medical care with the development of innovative IgG based therapeutics tailored to treat a wide range of diseases, such as cancer, neovascular eye diseases, and vascular related unmet needs. As a clinical stage public company, PharmAbcine is setting new standards in the industry to offer more effective treatments and improved outcomes.

Olinvacimab, the Company’s lead clinical stage asset, has the potential to be a revolutionary development in the field and is closely supported by its IND-ready preclinical assets PMC-309 and PMC-403, both first-in-class potential medicines. This pipeline is pushing boundaries in the fight against some of the world’s most debilitating illnesses.

The Company’s lead asset olinvacimab has shown impressive results in its Phase Ib olinvacimab-pembrolizumab trial, delivering a 50% overall response rate and a 67% disease control rate, plus a clean safety profile.

Now they are joining forces with MSD to embark on a Phase II trial, specifically targeting metastatic triple-negative breast cancer patients in Australia. Hopefully the results from this enhanced partnership will surpass the great success recorded in the previous trial.

PMC-309 is a revolutionary anti-VISTA-antagonizing IgG designed to combat immune checkpoint-associated disease, specifically targeting MDSC and M2 macrophages found in the tumor microenvironment.

Developed at an optimized pH level, it is poised to revolutionize the way we fight immune-mediated diseases, restoring balance to the body’s delicate immunomodulatory equilibrium.

PMC-403 is a revolutionary advancement in treatments for vascular-related eye diseases, such as wet AMD! This unique TIE2-activating antibody has been specifically developed to reduce the symptoms of this common age-related condition, stabilizing leaky and disorganized vessels and bringing hope to those affected.

PMC-005 is an exciting early-stage asset that has many potential applications! This anti-EGFRviii IgG has the ability to specifically bind to the cancer cell-expressing EGFRviii, allowing it to be used in a variety of modalities including CAR-T, CAR-NK, CAR-Macrophage, T cell/NK cell engager, and Radio-Immunotherapy. With the potential to make a major impact on cancer treatments, PMC-005 is sure to be a game-changer in the medical field.

Leave a Comment